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The most versatile treatment for inherited disorders is to precisely replace a 20 mutated sequence with its wildtype counterpart, thereby "normalizing" the genome. 21
We developed a single AAV platform that allows this in retinal neurons with 22 combined CRISPR-Cas9 and micro-homology-mediated end-joining. In blind mice, 23 the platform rescued ~10% of the retinal neurons, resulting in an incredible 24 ~10,000-fold improvement in light sensitivity, equivalent to the restoration 25 mediated by conventional gene augmentation therapy. 26 27 Gene supplementation of wildtype copies of functionally defective genes (gene 28 augmentation) mediated by adeno associated virus (AAV) have shown remarkable success 29 in clinical trials for inherited neural disorders. 1,2 However, its application is restricted to 30 limited genes within the capacity (~5,000 bps) of AAV. 3 CRISPR-Cas9-mediated allele 31 knock-out based on error-prone non-homologous end joining (NHEJ) can correct gain-of-32 function mutations with AAV. 4-7 However, many loss-of-function mutations in larger genes 33 still require local replacement with a wildtype sequence (scarless genome editing). 34
Here, we used micro-homology-mediated end-joining (MMEJ) to integrate a donor 35 template with micro-homology arms of 20 bp 8 as the basis for a new single-AAV platform 36 for scarless genome editing. First, we generated mutants of the preexisting retina-specific 37 promoters and conducted in vivo AAV reporter assays ( Fig. S1a -c, Table S1 ). The smallest 38 promoter that maintained neural retina-specific transcription was a 93-bp mutant GRK1 39 promoter that allowed reporter expression in 65.5% of the photoreceptors ( Fig. S1b-e ). This 40 was used to drive SaCas9 (3.2 Kb) expression. 41
We tested our single-AAV vector platform in Gnat1 IRD2/IRD2 /Pde6c cpfl1/cpfl1 mice 42 (double-mutant mice); the Gnat1 and Pde6c defects caused functional lack of rod and cone 43 photoreceptors, 9 respectively. The mice were essentially blind from birth and thus allowed 44 clear delineation of therapeutic effects. 10 We used our platform to correct IRD2 mutations in 45 Gnat1; these mutations constitute a homozygous 59-bp deletion in intron 4, preventing 46 protein expression in the rod photoreceptors 11 , which comprise ~75% of the murine retinal 47 cells. 12 Six guide RNAs (gRNAs) designed flanking the mutation were assessed with a T7 48
Endonuclease 1 (T7E1) assay ( Fig. S2 ). A gRNA pair (1+4) that excised the mutation most 49 efficiently was selected. The constructed single-AAV vector (Fig. 1a ) was then injected sub-50 retinally in 6-month-old double-mutant mice. Five weeks later, histology showed scattered 51 GNAT1-positive photoreceptors, indicating successful genome editing ( Fig. 1b ). T7E1 52 assay ( Fig. 1c ) and RT-PCR ( Fig. 1d ) of the whole retina revealed absolute editing 53 efficacies of 8.6% and 12.7% among the rod photoceptors, respectively. Furthermore, 54 electroretinogram (ERG), which reflects the number of functional photoreceptors, revealed 55 6-Hz flicker responses, averaging 11.4% of the control mice (Fig. 1e) . These results are 56 consistent with a ~10% rescue of the rod photoreceptors by genome editing. 57
Next, light sensitivity in the visual cortex was assessed with flash visually evoked 58 potentials (fVEPs). Surprisingly, cortical responses contralateral to the treated eye revealed 59 a ~10,000-fold (range: 1,000 -100,000-fold) improvement in light sensitivity, equivalent to 60 gene augmentation in ~70% of the photoreceptors ( Fig. 1f and g, S1e, S3). 10 This was 61 reflected by changes in light-induced behavior (fear conditioning, Fig. 1h ). Furthermore, 62 contralateral cortical responses to phase-reversal gratings, i.e., the pattern VEP (pVEP), 63
were detected in higher resolution gratings with larger amplitudes following the treatment, 64
indicating improved visual acuity (Fig. 1i ). Threshold assessment by measuring optokinetic 65 responses to rotating gratings showed visual acuity restoration in the treated mice to 59.1% 66 of the control mice. (Fig. 1j) . 67
On-target analysis of retinal genomic DNA with sequencing revealed an absolute 68 indel rate of 36.4% (Table S3 ), somewhat higher than previous reports 13, 14 . Three sites 69 predicted to have the highest off-target probabilities for each gRNA showed no detectable 70 mutation events in the retinal genomic DNA (Fig. S4) by the T7E1 assay. Further 71 sequencing of these sites found no mutations (Fig. S4) . 72
We also used our AAV vector to treat 2-month-old Gnat1 IRD2/IRD2 mice, which retain 73 cone function and serve as a model of human retinal dystrophy. 15 In the early course of the 74 disease, patients suffer from severe loss of light sensitivity with preserved visual acuity. 15 A 75 histological analysis showed scattered GNAT1-postive photoreceptors in the treated mice 76 ( Fig. 2a) . T7E1 assay and RT-PCR measured absolute genome editing efficacy at 7.5% 77 and 7.2%, respectively (Fig. S5a,b ). fVEP showed a ~1,000-fold increase in light sensitivity 78 ( Fig. 2b) . This was confirmed behaviorally with fear conditioning (Fig. 2c ). However, the 79 improvement in retinal function could not be isolated from preexisting cone function with 80 ERG and visual acuity remained unchanged with pVEP, or OKR ( Fig. S5c-e ). These results 81
show that our platform had therapeutic effects also in a human disease model. 82
This study shows that scarless genome editing allows a striking improvement in 83 light sensitivity, the major biomarker adopted in the seminal clinical trials for retinal 84 dystrophy. 2 Moreover, the effect was equivalent to that of conventional gene augmentation 85 therapy 10 , a platform that is already in clinical use, 16 and was achieved with a single AAV 86 vector. This is a major step forward from the dual vector system used in previous studies on 87 donor-based in vivo genome editing in post-mitotic cells, which generally yielded an 88 absolute editing efficiency of less than ~5% 13,14,17,18 , compared to ~10% shown herein. 89
Additional important advantages of scarless genome editing include physiological and 90 6 uniform expression of the target gene, neither of which is possible with gene augmentation. 91
This may be critically important to avoid dose-related toxicity caused by both gene over-92 expression 19 and under-expression 20 , especially during long-term treatment in humans. 93
As a proof of concept, our platform for single AAV-mediated scarless genome 94 editing demonstrates amelioration of key features of dysfunctional neurons. This paves the 95 way to treat inherited neural disorders caused by loss-of-function mutations in larger genes, 96
for which conventional gene augmentation therapy or NHEJ-based genome editing 97 strategies are not currently feasible. 98 99
